p.51 抽出テキスト

September 10, 2019 Circulation. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678 e646

CLINICAL STATEMENTS AND GUIDELINES Arnett et al 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Ron Blankstein ASPC Co-Director, Cardiovascular Imaging Training Program, Associate Physician, Preventive Cardiology, Director,

Cardiac Computed Tomography, Brigham Health, Associate Professor in Medicine

and Radiology, Harvard Medical

School •  Ekos Corporation •  Amgen None None •  Amgen† •  Astellas† •  Sanofi-Aventis† •  American Society of Nuclear Cardiology (Officer, Director, Trustee, or other Fiduciary Role)† •  Intersocietal Accreditation Commission for Computed Tomography (Officer, Director, Trustee, or other Fiduciary Role)† •  Society of Cardiovascular Computed Tomography (Officer, Director, Trustee, or other Fiduciary Role)† None None

Jo-Ann Eastwood PCNA Associate Professor,

UCLA School of

Nursing None None None None None None None

Stuart Haines Content Reviewer—ACC/

AHA Professor of Pharmacy

Practice, University of

Mississippi None None •  Rx Instructional Systems* None •  American Association of Colleges of Pharmacy (Officer, Director, Trustee, or other Fiduciary Role)† None None

Michael Rich AGS Professor of Medicine, Washington University

School of Medicine in

St. Louis None None None None None None None

This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-withindustry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. *Significant relationship. †No financial benefit. AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; ASN, American Society for Nutrition; American Society of Preventive Cardiology; DSMB, Data and Safety Monitoring Board; FDA, US Food and Drug Administration; FEBS, Federation of European Biochemical Societies; JAMA, Journal of the American Medical Association; LDL-C, low-density lipoprotein cholesterol; NHLBI, National Heart, Lung, and Blood Institute; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; OHSU, Oregon Health & Science University; PCNA, Preventive Cardiovascular Nurses Association; PCORI, Patient-Centered Outcomes Research Institute; UCLA, University of California, Los Angeles; UF, University of Florida; UPMC, University of Pittsburgh Medical Center; UT, University of Texas; UW, University of Wisconsin; and VA, Veterans Affairs.

Appendix 3.  Continued

Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/

Principal Personal Research Institutional, Organizational,

or Other Financial Benefit Expert Witness Salary

Downloaded from http://ahajournals.org by on October 7, 2026